Neuphoria Therapeutics Inc. Form DEF 14A: Definitive proxy statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-09-18: Form DEF 14A; Period of report 2026-11-02; Description DEF 14A; Document ny20081637x1_def14a.htm.
- 2025-10-30: Form DEF 14A; Period of report 2025-12-09; Description DEF 14A; Document ny20055722x1_def14a.htm.
- 2024-11-12: Form DEF 14A; Period of report 2024-12-11; Description DEFINITIVE PROXY STATEMENT; Document ea0218389-def14a_bionomics.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-09-18 | DEF 14A | 2026-11-02 | DEF 14A | ny20081637x1_def14a.htm |
| 2025-10-30 | DEF 14A | 2025-12-09 | DEF 14A | ny20055722x1_def14a.htm |
| 2024-11-12 | DEF 14A | 2024-12-11 | DEFINITIVE PROXY STATEMENT | ea0218389-def14a_bionomics.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |